Libor Gabalec

Libor Gabalec

Auto-generated profile, based on publicly available information

Libor Gabalec

Orlickoustecka Nemocnice a.s., Department of Internal Medicine , Ústí nad Orlicí , Czech Republic

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2016 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
DRDavid T. Rubin
David T. Rubin
MBMarc Bradette
Marc Bradette
LGLibor Gabalec
Libor Gabalec
DDDaniela Ecaterina Dobru
Daniela Ecaterina Dobru
JMJuan Márquez
Juan Márquez
OGon behalf of the Ulcerative Colitis Remission Study Group
on behalf of the Ulcerative Colitis Remission Study Group
This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine. In this phase 3b/4, open-label, multicentre, prospective, single-arm study, patients with mild-to-moderate ulcerative colitis were treated with multimatrix mesalazine 4.8g/day once daily for 8 weeks [induction phase]. At Week 8, those who achieved complete or partial remission, based on predefined clinical and endoscopic criteria, were eligible to receive 12 months of multimatrix mesalazine 2.4g/day once daily maintenance therapy. The primary endpoint was the proportion of patients in complete remission at Month 12. A total of 717 patients received induction treatment; 25.9% and 39.3% of patients achieved complete and partial remission, respectively, at Week 8. A total of 461 patients entered the maintenance phase. The likelihood of remaining in/achieving complete remission at Month 12 was higher for patients who entered the maintenance phase in complete remission compared with those who began maintenance in partial remission [47.8% vs 26.0%; p < 0.001]. At Month 12, mucosal healing [endoscopy score ≤ 1] was demonstrated in 76.4% [139/182] and 63.5% [176/277] of those who were in complete and partial remission, respectively, at the end of induction. Patients achieving complete remission before dose reduction were more likely to remain in remission at Month 12.

26 April 2018 in Gastroenterologie a hepatologie
Verified
Journal Article
Closed access
GRGabriela Růžičková
Gabriela Růžičková
LGLibor Gabalec
Libor Gabalec